Clinical trials: Amisulpride
PONV
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
- Trial name
- NCT02337062
- Testing
- APD421
- Where
- 25 sites in United States, France and 1 more
- Volunteers
- 1,147 people
- Sponsor
- Acacia Pharma Ltd
Healthy
Thorough QT Study of Intravenous Amisulpride
Randomised, single-dose, crossover, placebo-controlled study to see if intravenous amisulpride has any effect on the heart rhythm, in particular the QT interval, in healthy adult volunteers.
- Trial name
- NCT02661594
- Testing
- APD421 5 mg, APD421 40 mg, Moxifloxacin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
- Trial name
- NCT02646566
- Testing
- APD421
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 705 people
- Sponsor
- Acacia Pharma Ltd
PONV
US Phase III Study of APD421 in PONV
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT01991860
- Testing
- APD421- Amisulpride for IV injection
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- Acacia Pharma Ltd
PONV
European Phase III Study of APD421 in PONV
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT01991821
- Testing
- APD421
- Where
- 2 sites in France, Germany
- Volunteers
- 368 people
- Sponsor
- Acacia Pharma Ltd
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd